These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6251301)

  • 21. Postinfection treatment with antiviral serum results in survival of neural cells productively infected with virulent poliovirus.
    Tolskaya EA; Ivannikova TA; Kolesnikova MS; Drozdov SG; Agol VI
    J Virol; 1992 Aug; 66(8):5152-6. PubMed ID: 1321295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poliovirus type 3/Saukett: antigenic and structural correlates of sequence variation in the capsid proteins.
    Huovilainen A; Kinnunen L; Pöyry T; Laaksonen L; Roivainen M; Hovi T
    Virology; 1994 Feb; 199(1):228-32. PubMed ID: 8116248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenic potency of inactivated poliovirus vaccines.
    Moynihan M; Petersen I
    Dev Biol Stand; 1981; 47():129-33. PubMed ID: 6262143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenic sites on type 2 poliovirus.
    Patel V; Ferguson M; Minor PD
    Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
    Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
    J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell clones cured of persistent poliovirus infection display selective permissivity to the wild-type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants.
    Calvez V; Pelletier I; Couderc T; Pavio-Guédo N; Blondel B; Colbère-Garapin F
    Virology; 1995 Oct; 212(2):309-22. PubMed ID: 7571400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of single-radial-diffusion and autoradiographic zone size enhancement (ZE) techniques for poliovirus antigens.
    Schild GC; Wood JM; Minor PD; Dandawate CN; Magrath DI
    Dev Biol Stand; 1981; 47():77-85. PubMed ID: 6262163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
    Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
    Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Application of the isofixation technic in the complement fixation test for the intratypical differentiation of polio virus strains of type I].
    Thraenhart O; Kuwert E
    Z Immunitatsforsch Allerg Klin Immunol; 1967 Feb; 132(2):147-64. PubMed ID: 4296226
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiviral activity of IgG subclasses in guinea pig antiserum.
    Togashi H; Tanaka Y; Tozawa H
    Kitasato Arch Exp Med; 1981 Dec; 54(3-4):55-61. PubMed ID: 6296525
    [No Abstract]   [Full Text] [Related]  

  • 31. Murine neurovirulence studies with a chimeric poliovirus: in vivo generation of a mutant base-paired stable attenuated poliovirus.
    Lee C; Young C
    Microb Pathog; 1998 Oct; 25(4):215-25. PubMed ID: 9817825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The specificity and interaction with poliovirus of an inhibitory bovine serum.
    Pagano JS; Gilden RV; Sedwick WD
    J Immunol; 1965 Nov; 95(5):909-17. PubMed ID: 4284837
    [No Abstract]   [Full Text] [Related]  

  • 33. Vaccines based on recombinant antigen strategies.
    Minor P
    Dev Biol (Basel); 2001; 105():189-94. PubMed ID: 11763327
    [No Abstract]   [Full Text] [Related]  

  • 34. Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.
    Crainic R; Blondel B; Horaud F
    Dev Biol Stand; 1983; 55():185-9. PubMed ID: 6329856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poliovirus resistant cells derived from HeLa cells.
    Chinami M; Nakamura E; Kakisako S; Xu B; Shingu M
    Kurume Med J; 1986; 33(3):125-9. PubMed ID: 3037186
    [No Abstract]   [Full Text] [Related]  

  • 36. Influence of the mutant spectrum in viral evolution: focused selection of antigenic variants in a reconstructed viral quasispecies.
    Martín V; Domingo E
    Mol Biol Evol; 2008 Aug; 25(8):1544-54. PubMed ID: 18436553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
    Whelan SP; Evans D; Almond JW
    Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
    [No Abstract]   [Full Text] [Related]  

  • 38. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
    Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
    Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Studies of purification, inactivity and immunogenicity of antigenically chimeric poliovirus].
    Cai H; Dai C
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Oct; 15(5):349-53. PubMed ID: 8168218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Poliovirus antigen concentrations by means of polyethylenglycol 6000 (author's transl)].
    Kucharaská Z; Zdrazílek J; Koza J
    Cesk Epidemiol Mikrobiol Imunol; 1977 Nov; 26(6):344-9. PubMed ID: 205374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.